Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of dialysis-like therapies for cardiovascular disease and cancer, released a shareholder update from CEO Jim Joyce detailing the company's strategic initiatives, including potential mergers and asset sales. The update highlights the therapeutic potential of CardioDialysis, a device designed to reduce cholesterol-transporting lipoproteins and inflammatory molecules, which could be used in over 7,500 dialysis clinics in the United States. This positions CardioDialysis as a significant opportunity in cardiovascular care, especially given the limited availability of current lipoprotein apheresis devices to fewer than 60 specialized centers.
Joyce, who previously founded Aethlon Medical and led the Hemopurifier to FDA breakthrough designations, emphasized that CardioDialysis targets multiple drivers of life-threatening conditions, including cardiovascular disease, sepsis, and traumatic brain injury. He noted the absence of approved therapies for sepsis and cited Spectral Medical's PMX device as a leading candidate, while pointing out that CardioDialysis has been validated to reduce sepsis-inducing bacterial toxins and inflammatory mediators.
The update also addressed the company's financial and operational hurdles. Sigyn became public through a merger with an OTC company but failed to execute an uplist to Nasdaq due to regulatory catch-22 between SEC and Nasdaq requirements. Joyce acknowledged that while share price and exchange do not affect therapeutic efficacy, they have hindered capital raising without diluting shareholder value. He referenced a January 15th shareholder update outlining strategies to reduce dilution, including potential asset sales and a merger with a Nasdaq-listed company at risk of not meeting the $5 million minimum market value of listed securities requirement.
Joyce concluded by thanking shareholders and noting that the company has 2,330,042 shares outstanding as of March 11, 2026. The update reflects Sigyn's efforts to advance its therapies while navigating financial challenges, with the goal of delivering value through strategic transactions.
